Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, 6229 ER Maastricht, The Netherlands.
Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Int J Mol Sci. 2022 Feb 13;23(4):2061. doi: 10.3390/ijms23042061.
The phenomenon of individual variability in susceptibility/resilience to stress and depression, in which the hippocampus plays a pivotal role, is attracting increasing attention. We investigated the potential role of hippocampal cyclooxygenase-2 (COX-2), which regulates plasticity, neuroimmune function, and stress responses that are all linked to this risk dichotomy. We used a four-week-long chronic mild stress (CMS) paradigm, in which mice could be stratified according to their susceptibility/resilience to anhedonia, a key feature of depression, to investigate hippocampal expression of COX-2, a marker of microglial activation Iba-1, and the proliferation marker Ki67. Rat exposure, social defeat, restraints, and tail suspension were used as stressors. We compared the effects of treatment with either the selective COX-2 inhibitor celecoxib (30 mg/kg/day) or citalopram (15 mg/kg/day). For the celecoxib and vehicle-treated mice, the Porsolt test was used. Anhedonic (susceptible) but not non-anhedonic (resilient) animals exhibited elevated COX-2 mRNA levels, increased numbers of COX-2 and Iba-1-positive cells in the dentate gyrus and the CA1 area, and decreased numbers of Ki67-positive cells in the subgranular zone of the hippocampus. Drug treatment decreased the percentage of anhedonic mice, normalized swimming activity, reduced behavioral despair, and improved conditioned fear memory. Hippocampal over-expression of COX-2 is associated with susceptibility to stress-induced anhedonia, and its pharmacological inhibition with celecoxib has antidepressant effects that are similar in size to those of citalopram.
个体对压力和抑郁的易感性/适应能力的变化现象,其中海马体起着关键作用,正引起越来越多的关注。我们研究了海马体环氧化酶-2(COX-2)的潜在作用,COX-2 调节可塑性、神经免疫功能和应激反应,这些都与这种风险二分法有关。我们使用了为期四周的慢性轻度应激(CMS)范式,根据它们对快感缺失(抑郁的一个关键特征)的易感性/适应能力,将小鼠分层,以研究海马体 COX-2 的表达、小胶质细胞激活标志物 Iba-1 和增殖标志物 Ki67。大鼠暴露、社会挫败、束缚和悬尾被用作应激源。我们比较了用选择性 COX-2 抑制剂塞来昔布(30mg/kg/天)或西酞普兰(15mg/kg/天)治疗的效果。对于塞来昔布和载体处理的小鼠,进行了 Porsolt 测试。快感缺失(易感)但非快感缺失(适应)动物表现出 COX-2 mRNA 水平升高、齿状回和 CA1 区 COX-2 和 Iba-1 阳性细胞数量增加以及海马体颗粒下区 Ki67 阳性细胞数量减少。药物治疗降低了快感缺失小鼠的比例,使游泳活动正常化,减少了行为绝望,并改善了条件性恐惧记忆。海马体 COX-2 的过度表达与应激诱导的快感缺失易感性有关,其药理学抑制作用用塞来昔布具有与西酞普兰相似大小的抗抑郁作用。